Overview

Of all the comparisons between incretin drugs, retatrutide versus tirzepatide may teach us the most. The same Eli Lilly research group developed both. They share two receptor targets (GIP and GLP-1) and differ in exactly one respect: retatrutide also activates the glucagon receptor and tirzepatide does not. That makes the pair a natural experiment in what glucagon receptor activation adds.

Tirzepatide is FDA-approved as Mounjaro (for type 2 diabetes) and Zepbound (for obesity). Retatrutide is still in Phase 3 development and not yet approved for any use.

TRIUMPH-4’s Phase 3 data, showing -28.7% mean weight loss at 68 weeks, have made the size of the difference clearer. Phase 3 confirmation matters because promising Phase 2 results usually shrink in larger, more varied populations. With retatrutide, the Phase 3 data actually beat Phase 2.

Important caveat: No head-to-head clinical trial of these two molecules has reported results. Every comparison below is cross-trial and has built-in limits, including differences in patient populations, study length, dose-escalation schedules and endpoint definitions. Lilly’s TRIUMPH-5 trial compares retatrutide directly with tirzepatide; it is still running, with primary completion expected in November 2026.

Even so, this cross-trial comparison is one of the easier ones to interpret. The same manufacturer, similar patient populations and identical dosing frequency remove some of the confounding that muddies other cross-trial comparisons.

Mechanism of Action

Shared Pathways: GIP and GLP-1

Both retatrutide and tirzepatide activate GIP and GLP-1 receptors, providing:

Glucose-dependent insulin secretion (GIPR and GLP-1R)
Appetite suppression (GLP-1R and GIPR central effects)
Slowed gastric emptying (GLP-1R)
Glucagon suppression (GLP-1R)
Adipose tissue modulation (GIPR)

Both molecules are most potent at the GIP receptor, reflecting a shared design idea: strong GIPR activation amplifies the metabolic effects of GLP-1R activation.

The Differentiating Factor: Glucagon Receptor

The key difference is retatrutide’s glucagon receptor activity, which tirzepatide lacks. The GCGR component provides:

More energy use: Glucagon switches on heat-producing pathways in the liver and possibly in brown fat, raising the calories the body burns at rest
More fat burning in the liver: It directly promotes fat burning in liver cells, driving large drops in liver fat
Amino acid breakdown: The liver processes more amino acids, with uncertain long-term clinical effects
Possible glucose-raising effect: Offset by the insulin release driven at the same time by GLP-1R and GIPR

This GCGR-driven rise in energy use is the main reason retatrutide appears to produce more weight loss than tirzepatide across trials. Retatrutide both cuts calorie intake (like tirzepatide) and raises calorie burning (unique to retatrutide).

Why the Third Receptor Matters

Adding glucagon to a dual agonist can sound odd, since glucagon raises blood sugar. But the logic holds. Glucagon’s metabolic role goes well beyond blood sugar: it is the body’s strongest signal for the liver to mobilize energy, driving fat burning, heat production and amino acid breakdown. Layered on top of the strong insulin release from GIP and GLP-1, glucagon’s glucose-raising effect is cancelled while its energy-burning effects remain. The result is a molecule that works on both sides of energy balance: less intake and more expenditure.

Efficacy Comparison

Weight Loss

Cross-trial comparison including Phase 3 TRIUMPH-4 data:

Parameter	Tirzepatide 15 mg	Retatrutide 12 mg (Phase 2)	Retatrutide (TRIUMPH-4, Phase 3)
Trial	SURMOUNT-1 (Phase 3)	Phase 2 obesity	TRIUMPH-4 (Phase 3)
Duration	72 weeks	48 weeks	68 weeks
Mean weight loss	-22.5%	-24.2%	-28.7%
≥5% weight loss	~91%	~100%	Not in topline release
≥10% weight loss	~79%	~93%	Not in topline release
≥15% weight loss	~62%	~83%	Not in topline release
≥20% weight loss	~48%	~73%	Not in topline release
≥25% weight loss	—	—	58.6%
≥30% weight loss	—	—	39.4%

The TRIUMPH-4 Phase 3 data matter because they did more than confirm the Phase 2 signal; they beat it. No obesity drug had ever produced -28.7% mean weight loss at 68 weeks in a Phase 3 population. Tirzepatide reached -22.5% at 72 weeks; retatrutide reached -28.7% at 68 weeks, in less time. That strongly suggests the glucagon component adds a clinically meaningful amount of weight loss.

Understanding the Phase 2 to Phase 3 Transition

In drug development, Phase 3 results often fall short of Phase 2. Phase 2 trials are smaller, often enroll more carefully selected people and run under tighter control. Tirzepatide followed this pattern: SURMOUNT-1 delivered slightly different results than the earlier dose-finding studies.

Retatrutide’s TRIUMPH-4 broke the pattern. Its Phase 3 weight loss of -28.7% beat the Phase 2 result of -24.2%, probably thanks to refined dose escalation and better understanding of the drug. That makes the clinical profile much more convincing.

Weight Loss Responder Analysis

Beyond the average, the share of patients who reach meaningful thresholds shows how consistent the response is. In SURMOUNT-1, about 91% of patients on tirzepatide 15 mg lost at least 5%, and about 48% lost at least 20%. In retatrutide’s Phase 2 trial, almost everyone (about 100%) lost at least 5%, and about 73% lost at least 20%. Lilly’s TRIUMPH-4 topline release reported that 58.6% of participants on 12 mg lost at least 25% and 39.4% lost at least 30% of body weight (efficacy estimand); lower thresholds were not reported.

These figures matter clinically because they speak to consistency. A drug with a high average but wide spread may leave many patients without enough response. Both tirzepatide and retatrutide seem to produce fairly consistent responses, with most patients losing at least 10%, a threshold linked to real improvements in cardiometabolic risk factors.

Glycemic Control

Both molecules lower blood sugar strongly in type 2 diabetes. Tirzepatide cut HbA1c by about 2.0-2.4% in the SURPASS Phase 3 program, with many participants reaching HbA1c <7%. Retatrutide cut it by up to 2.02% in Phase 2 (24 weeks). These are broadly similar, which suggests adding glucagon receptor activation does not much improve blood sugar control beyond dual GIP/GLP-1 action. That fits the expectation that GCGR’s glucose-raising effect cancels out part of any extra benefit.

Liver Fat

This is where the glucagon component seems to make the biggest difference:

Parameter	Tirzepatide	Retatrutide
Relative liver fat reduction	~50-60%	~82%
MASLD resolution rate	Data limited	Data pending (Phase 3)
Mechanism	Indirect (weight loss, improved insulin sensitivity)	Direct (GCGR hepatic effects) + indirect

The roughly 20-30 percentage point gap in liver fat reduction is thought to come from GCGR-driven fat burning in the liver itself, which tirzepatide, without glucagon receptor activity, cannot reproduce. For the growing number of people with metabolic dysfunction-associated steatotic liver disease (MASLD), this may be the most clinically relevant difference between the two drugs.

The biology behind retatrutide’s liver advantage is well understood. Glucagon receptor signaling in liver cells directly stimulates fat burning in the mitochondria (beta-oxidation), in effect telling liver cells to burn their stored fat. That is very different from the indirect liver fat loss that comes with weight loss alone.

Safety Comparison

Gastrointestinal Events

Both drugs have similar GI side effects, driven by GLP-1R and GIPR activation:

Adverse Event	Tirzepatide 15 mg (Zepbound US label, SURMOUNT-1 and -2 pooled)	Retatrutide 12 mg (TRIUMPH-4, 68 weeks)
Nausea	28%	43.2%
Diarrhea	23%	33.1%
Vomiting	13%	20.9%
Constipation	11%	25.0%

In these figures, retatrutide’s GI rates are higher than tirzepatide’s in every category (nausea 43.2% vs 28%, diarrhea 33.1% vs 23%). The glucagon component or the drug’s greater overall potency may play a part. These are cross-trial comparisons; the head-to-head TRIUMPH-5 trial has not reported. Both drugs raise the dose gradually to limit GI side effects at the start.

Cardiovascular Parameters

Both drugs improve cardiovascular risk factors, including blood pressure and lipids. Both raise heart rate. The Zepbound label reports a mean increase of 1 to 3 beats per minute, with no increase on placebo. In retatrutide’s Phase 2 obesity trial, heart rate rose with dose, peaked at 24 weeks and then declined; the main paper does not give the size of the rise. Tirzepatide is further along in cardiovascular safety testing: its SURPASS-CVOT trial in type 2 diabetes reported in July 2025, showing non-inferiority to dulaglutide for major adverse cardiovascular events (HR 0.92).

Dysesthesia

TRIUMPH-4 Phase 3 data found a new safety signal for retatrutide: dysesthesia (tingling, numbness or burning sensations), reported in 20.9% of the 12 mg group versus 0.7% on placebo. It was not prominent in Phase 2 and is thought to be linked to glucagon receptor activity. Tirzepatide, which does not act on the glucagon receptor, has shown no similar signal in its clinical program, which supports a GCGR-specific cause.

Hepatic Effects

Both drugs look safe for the liver, with stable or improved liver enzymes. Retatrutide’s larger liver fat reduction may bring added long-term liver benefits, but the effects of years of GCGR activation on liver function need continued monitoring.

Body Composition Considerations

A key concern with large weight loss is losing lean body mass (muscle). Both drugs cause some lean mass loss along with fat loss, as any treatment that causes major weight loss does. Early data suggest the lean-to-fat ratio is acceptable with both, but it will be an important measure in retatrutide’s Phase 3 data, especially given the larger total weight loss.

Molecular Design

Feature	Tirzepatide	Retatrutide
Peptide length	39 amino acids	39 amino acids
Molecular weight	~4,814 Da	~4,731 Da
Backbone	GIP-based	GIP-based
Receptor targets	GIPR, GLP-1R	GIPR, GLP-1R, GCGR
GIPR potency	High	High
GLP-1R potency	Moderate	Moderate
GCGR potency	None	Moderate
Fatty acid	C20	C20
Half-life	~5 days	~6 days
Dosing	Once weekly SC	Once weekly SC

The two molecules look alike because both come from Eli Lilly’s peptide engineering platform and share a GIP-based backbone. Both use the same C20 fatty acid chain to bind albumin and extend half-life. The challenge with retatrutide was adding glucagon receptor activity to the GIP/GLP-1 scaffold without disturbing the existing receptor activity, which Lilly achieved with targeted amino acid changes.

Both molecules are 39 amino acids long, but retatrutide weighs slightly less (~4,731 Da vs. ~4,814 Da for tirzepatide) because of differences in amino acid makeup. Both are clear, colorless solutions injected under the skin and stored in the refrigerator. With similar pharmacokinetics (weekly dosing, comparable half-lives), taking either drug is essentially the same in practice.

Dose Titration and Treatment Initiation

Both drugs raise the dose gradually to manage GI side effects at the start. This is standard for incretin drugs and reflects the known link between GLP-1 receptor activation and GI side effects.

Tirzepatide dose escalation: Treatment starts at 2.5 mg weekly for 4 weeks, then rises by 2.5 mg every 4 weeks to a maintenance dose of 5 mg, 10 mg or 15 mg. The maximum approved dose is 15 mg. Reaching the top dose takes at least 16 weeks.

Retatrutide dose escalation: Clinical trials have moved from lower starting doses up to the 12 mg target. The titration schedule used in TRIUMPH-4 may differ from Phase 2 and will matter for clinical use. The refined Phase 3 titration may partly explain why efficacy improved on Phase 2.

The titration period matters because neither drug works at full strength right away. Expect modest effects at first that build as the dose rises. Sticking to the escalation schedule is important: skipping doses or moving up too fast raises the risk of GI side effects without improving long-term results.

Body Composition Effects

Weight loss is not all the same; what is lost matters. Losing fat is good for metabolism, while losing too much lean mass (muscle, bone) can be harmful, especially in older adults.

Both tirzepatide and retatrutide cause weight loss that is mostly fat. In tirzepatide’s SURMOUNT-1 trial, body composition analyses showed that about 60-70% of the weight lost was fat and the rest lean mass. That ratio is roughly what you would expect from calorie-deficit weight loss of this size.

Retatrutide’s Phase 2 body composition data are limited but suggest a similar pattern. Its glucagon component adds a theoretical twist. Glucagon speeds amino acid breakdown, which could in theory speed lean mass loss. But it also promotes fat burning in the liver, which could shift the body’s fuel away from amino acids and toward fat, possibly protecting lean mass. The net effect is still an important question for the Phase 3 program.

If you are worried about muscle loss, either drug should ideally be paired with enough protein (at least 1.2-1.6 g/kg/day) and resistance exercise. Clinical guidelines increasingly stress that obesity drugs should be prescribed within a full lifestyle program that includes dietary counseling and physical activity, not as a standalone treatment. This matters most with drugs that produce more than 20% weight loss, where the absolute amount of lean mass lost becomes clinically significant.

Body composition data from DEXA (dual-energy X-ray absorptiometry) scans in Phase 3 trials of both drugs will be critical for guidance on exercise and protein during treatment.

Current Status and Availability

Parameter	Tirzepatide	Retatrutide
Regulatory status	FDA-approved (Mounjaro, Zepbound)	Investigational (Phase 3)
Available for prescription	Yes	No
Phase 3 data	Complete (SURMOUNT, SURPASS programs)	Ongoing (TRIUMPH program)
Expected approval	Already approved	Late 2027 to mid-2028 (filing planned no later than Q1 2027)
Brand names	Mounjaro (T2D), Zepbound (obesity)	None assigned
Insurance coverage	Variable, expanding	Not applicable
Cost (list price)	Above $1,000/month (Zepbound launched at $1,059.87 in 2023)	Unknown

Tirzepatide is available today by prescription. Retatrutide can only be obtained by enrolling in a clinical trial. If you are interested in retatrutide, ask your doctor about trial eligibility, but do not buy it from unregulated sources. Unregulated peptides come with no guarantee of quality, sterility or accurate dosing.

Eli Lilly Portfolio Strategy

Having both tirzepatide and retatrutide raises strategic questions for Eli Lilly. Rather than competing products, they likely form a tiered approach to metabolic treatment:

Tirzepatide: A proven, approved dual agonist for broad use in obesity and diabetes
Retatrutide: A potentially more potent triple agonist for patients who need more weight loss, have significant liver fat, or do not respond well enough to dual agonism

If retatrutide is approved, this tiering would let doctors match treatment intensity to each patient’s needs. It also gives Eli Lilly a unique position: no other company has both a dual and a triple agonist, covering the full range of metabolic disease severity.

Patient Population Considerations

Obesity Without Diabetes

For people with obesity but no type 2 diabetes, how much weight comes off is the main measure. Tirzepatide (as Zepbound) delivers ~21% weight loss. Retatrutide’s ~29% is a big step up. For people with BMI ≥40, or those hoping to avoid bariatric surgery, the extra weight loss could decide whether they reach a life-changing health result.

Type 2 Diabetes

People with type 2 diabetes usually lose less weight than people without it, a pattern seen with all incretin drugs. Tirzepatide (as Mounjaro) produces about 12-15% weight loss in people with diabetes, with excellent blood sugar control (HbA1c reductions of 2.0-2.4%). Retatrutide’s Phase 2 diabetes data showed -16.9% weight loss with an HbA1c reduction of -2.02%. In Phase 3, TRIUMPH-2 (obesity with type 2 diabetes) reported -20.8% weight loss and an A1C reduction of 1.5 points at 12 mg over 80 weeks, and TRANSCEND-T2D-1 reported an A1C reduction of 1.94 points and -15.3% weight loss at 12 mg over 40 weeks.

MASLD/MASH

For the growing number of people with metabolic dysfunction-associated steatotic liver disease, retatrutide’s ~82% liver fat reduction may make it the most effective drug option. Tirzepatide’s ~50-60% reduction is clinically meaningful but does not match retatrutide’s direct glucagon-driven liver effects. If retatrutide improves liver tissue in MASH (inflammation and fibrosis), it could become a first-line treatment for the condition.

Cardiovascular Risk

Neither drug has completed cardiovascular outcomes trials of its own. Tirzepatide has more mature cardiovascular safety data from its large Phase 3 program and post-marketing surveillance. For patients focused on lowering cardiovascular risk, current evidence favors tirzepatide, though dedicated CVOT data would firm up the comparison.

What the Comparison Tells Us About Glucagon

Retatrutide versus tirzepatide is essentially a test of what glucagon receptor activation adds to a GIP/GLP-1 dual agonist. On the data so far:

More weight loss: Likely from higher energy use (the calories-out side of energy balance). The TRIUMPH-4 data (-28.7% vs. tirzepatide’s -22.5%) suggest the extra is about 6 percentage points, a clinically meaningful difference.
More liver fat reduction: From direct fat burning in the liver (~82% vs. ~50-60% relative reduction)
Similar blood sugar control: GCGR’s glucose-raising effect is offset by the other pathways
GI tolerability: GI rates in TRIUMPH-4 were higher than in SURMOUNT-1 (a cross-trial comparison), so GCGR or the greater overall potency may add to the GI burden
Broader metabolic effects: Especially on the liver and heat production

Cost and Access Considerations

Cost weighs heavily in obesity treatment decisions, and the tirzepatide-retatrutide comparison will eventually include a cost-effectiveness question.

Tirzepatide (current): Mounjaro and Zepbound have list prices above $1,000 per month. As of October 2026, LillyDirect sells self-pay Zepbound for $299 to $449 a month depending on dose, and since July 1, 2026 eligible Medicare Part D enrollees can get the Zepbound KwikPen for $50 a month through the temporary Medicare GLP-1 Bridge. Insurance coverage varies and is improving, especially for Mounjaro (diabetes). Out-of-pocket costs are still a big barrier for many people, and the cost-effectiveness debate continues.

Retatrutide (projected): The price is unknown, but given its stronger efficacy, Eli Lilly may charge more than for tirzepatide. In cost-effectiveness terms, though, more weight loss per dollar could favor retatrutide if the extra weight loss leads to proportionally fewer related diseases, hospital stays and long-term healthcare costs.

Value will come down to whether retatrutide’s extra ~6 percentage points of weight loss lead to proportional gains in hard outcomes (cardiovascular events, diabetes remission, cancer risk, deaths) that justify any higher price. Those outcome data will take years to gather.

Long-Term Considerations

Weight Regain After Discontinuation

A key question for both drugs is what happens when treatment stops. Tirzepatide data (SURMOUNT-4) show significant regain after stopping: about two-thirds of lost weight returns within one year. The same holds across GLP-1-based drugs, which suggests they must be taken long term to keep the benefit.

Whether retatrutide behaves the same way is unknown. Its glucagon component’s effect on metabolic rate could in theory leave some lasting benefit after stopping (by shifting the body’s metabolic set point), but that is speculation. If retatrutide also has to be taken long term, its long-term safety and cost matter even more.

Combination Therapy Potential

Either drug could eventually be combined with other medicines to boost efficacy or target specific conditions. For tirzepatide, pairings with SGLT2 inhibitors or orlistat have been discussed. For retatrutide, the breadth of its receptor activity may weaken the case for combinations: when one molecule already hits three pathways, adding more drugs may bring little extra benefit.

Conclusion

Retatrutide and tirzepatide are close relatives that differ in one respect: glucagon receptor activation. TRIUMPH-4’s Phase 3 data confirmed that this extra receptor brings meaningful gains in weight loss (-28.7% vs. -22.5%) and, based on earlier data, liver fat reduction, without hurting blood sugar control, though with higher GI rates and a dysesthesia signal.

Tirzepatide is still the more established option, with years of clinical use, regulatory approval and extensive real-world data. Retatrutide has passed the critical Phase 3 efficacy hurdle but still needs to finish its broader Phase 3 program and win regulatory approval before patients can get it. If you do well on tirzepatide, there may be no reason to change. If you need more weight loss or have significant fatty liver, retatrutide could one day offer a real step up within the same drug family.

Summary of Key Data Points

Metric	Tirzepatide 15 mg	Retatrutide (TRIUMPH-4)
Phase 3 weight loss	-22.5% (72 weeks)	-28.7% (68 weeks)
Phase 2 weight loss	N/A (dose-finding)	-24.2% (48 weeks)
Liver fat reduction	~50-60%	~82%
HbA1c reduction (T2D)	-2.0 to -2.4%	-2.02%
Nausea rate (Zepbound label; retatrutide 12 mg)	28%	43.2%
Diarrhea rate	23%	33.1%
Vomiting rate	13%	20.9%
Half-life	~5 days	~6 days
Receptors	GIP + GLP-1	GIP + GLP-1 + Glucagon
Approval status	FDA-approved	Phase 3
Earliest availability	Now	Late 2027 to mid-2028

Frequently Asked Questions

Is retatrutide more effective than tirzepatide for weight loss?

Cross-trial data suggest yes. Retatrutide’s Phase 3 TRIUMPH-4 trial showed -28.7% mean weight loss at 68 weeks, compared with tirzepatide’s -22.5% at 72 weeks in SURMOUNT-1. That gap of about 6 percentage points, reached in less time, is clinically significant. But no head-to-head trial has reported, and cross-trial comparisons are limited by differences in study populations and design.

When will retatrutide be available compared to tirzepatide?

Tirzepatide is available now, approved as Mounjaro (type 2 diabetes) and Zepbound (obesity). Retatrutide is in Phase 3 clinical trials and has not been submitted for approval. The earliest realistic approval is late 2027 to mid-2028, with Lilly planning to file no later than Q1 2027 and assuming the review goes smoothly. The FDA ruled on October 2, 2026 that retatrutide is a drug, so the application must be a New Drug Application (NDA), which Lilly is contesting (the FDA ruling).

Do retatrutide and tirzepatide have the same side effects?

Both mainly cause gastrointestinal symptoms such as nausea, diarrhea and vomiting. Phase 3 TRIUMPH-4 data for retatrutide showed higher GI rates than tirzepatide: nausea 43.2% (vs 28% for tirzepatide 15 mg in the Zepbound label), diarrhea 33.1% (vs 23%) and vomiting 20.9% (vs 13%) at the 12 mg dose over 68 weeks. Both drugs raise the dose gradually to keep GI effects manageable.

Can you switch from tirzepatide to retatrutide?

Not outside clinical trials, because retatrutide is not yet approved. If it is approved, switching from tirzepatide would be a decision for you and your doctor. Both drugs act on GIP and GLP-1 receptors, which might make the switch easier. But retatrutide’s added glucagon activity means some dose titration would probably be needed. There are no clinical data on switching between them.

Which is better for reducing liver fat: retatrutide or tirzepatide?

Retatrutide appears to have a big advantage. Phase 2 data showed about an 82% relative drop in liver fat with retatrutide, compared with roughly 50-60% with tirzepatide. The difference comes from retatrutide’s glucagon component, which directly stimulates fat burning in the liver, in effect telling liver cells to burn their stored fat. For people with metabolic dysfunction-associated steatotic liver disease (MASLD), this may be the most important clinical difference between the two drugs.

Are retatrutide and tirzepatide made by the same company?

Yes. Eli Lilly and Company developed both. They share the same GIP-based peptide backbone and were created by the same research team, which included Dr. Tamer Coskun. That makes the comparison especially informative scientifically, because the main difference, retatrutide’s added glucagon receptor activity, can be studied fairly cleanly on its own.

Eli Lilly positions tirzepatide as the established first-line option and retatrutide as a possibly more potent second-tier treatment for patients who need stronger metabolic treatment. That gives the company unusual coverage across the range of metabolic disease severity: tirzepatide for broad use, retatrutide for patients who need maximum efficacy or have specific conditions like MASLD where the glucagon component adds benefit.